中源协和：全资子公司取得VUM02注射液《药物临床试验批准通知书》

Group 1 - The core point of the article is that Zhongyuan Qihua has received approval from the National Medical Products Administration for its VUM02 injection to treat severe/critical pneumonia, which could enhance its market position and revenue potential [1] - Zhongyuan Qihua's revenue composition for the first half of 2025 shows that manufacturing accounts for 68.9%, services for 28.3%, and other businesses for 2.79% [1] - As of the report, Zhongyuan Qihua has a market capitalization of 11.6 billion yuan [1]